The cardiac effect of thirty-eight diterpenoid alkaloids was evaluated on the isolated bullfrog heart model. Among them, twelve compounds exhibited appreciable cardiac activity, with compounds 3 and 35 being more active than the reference drug lanatoside. The structure-cardiac activity relationships of the diterpenoid alkaloids were summarized based on our present and previous studies [2]: i) 1-OMe or and NH (or NMe) are key structural features important for the cardiac effect of the aconitine-type C 19 -diterpenoid alkaloids without any esters. C 18 -diterpenoid alkaloids, lycoctoninetype C 19 -diterpenoid alkaloids, and the veatchine-and denudatine-type C 20 -diterpenoid alkaloids did not show any cardiac activity; ii) the presence of 3-OH is beneficial to the cardiac activity; iii) the effect on the cardiac action of 6-OMe, 13-OH, 15-OH, and 16-demethoxy or a double bond between C-15 and C-16 depends on the substituent pattern on the nitrogen atom.
Biological evaluation:
The cardiac effects of the forty-two diterpenoid alkaloids on isolated bullfrog hearts (Table 3) were evaluated according to the procedure described in the literature [7] . The cardiac effect was represented as the mean of amplitude increase rate and arbitrarily classified into four categories: no cardiac effect (the average rate of amplitude was increased in the range of 0-10%); moderate cardiac effect (12-30%); significant cardiac effect (31-59%); and strong cardiac effect (greater than 60%). It should be noted that N-deethylchasmaconine (8) mesaconine (9), hypaconine (10), and N-deethylaconine (11) have been previously reported by us [2] and were included in this study for better structure-activity comparison. The data are summarized in Table 3 , which indicates that fifteen (3, 8-11, 14, 17-18, 22, 24, 25 Structure-cardiac activity relationships of diterpenoid alkaloids Natural Product Communications Vol. 10 (12) 2015 2077 hypaconine (10), and compound 35 exhibit better cardiac effect than the reference drug lanatoside C.
A broad range (potent-to-inactive) of cardiac effects has been observed for the forty-two diterpenoid alkaloids with the following structure-activity relationships: 1) C 18 -diterpenoid alkaloids (e.g. 39, 40) or the aconitine-type alkaloids containing a monoester [e.g. 14-benzoylmesaconine (41) and 14-benzoylhypaconine (42)], the veatchine-type C 20diterpenid alkaloids (e. g. 43-48, 50, and 51) , and the denudatine-type C 20 -diterpenoid alkaloids (e.g. 53, 56 and 57) did not exhibit any apparent cardiac effect. Additionally, no considerable effect was observed for the aconitine-type alkaloids that contain an imine moiety (e.g. 36). 2) Consistent with the results that we previously reported [2] , the aminoalcohol group of aconitine-type C 19 -diterpenoid alkaloids bearing both hydroxyl groups at C-8 and C-14 are most essential structure features for the cardiac activity. The substituent pattern on the nitrogen atom (NH, NMe, or NEt), the hydroxyl group at C-3, C-15, and C-13, and the methoxyl group at C-6 can appreciably contribute to or abolish the activity. These can be specified as below: i) the alkaloids with a 3 -OH (e.g. 3, 4 and 18) are more potent than those without it (e.g. 8, 7, and 15), suggesting the presence of a 3 -OH is beneficial to the cardiac effect, which is consistent with the conclusions in our previous paper [2] ; ii) in addition to alkaloids 15 and 28, the alkaloids that possess a methyl group on the nitrogen atom [e.g. mesaconine (9), 22, 28, and 35] are more active than the corresponding compounds containing a hydrogen instead [e.g. N-deethylamine (11), 21, 27, and 34].
The similar effect of the NMe on the cardiac activity can also be concluded by comparing the activity of 24/23, 22/21, and 30/29. However, alkaloids that contain a NH moiety but no 13, 15 -OH (e.g. 3, 8, and 29) have greater activity than those with a NMe moiety (e.g. 4, 7, and 30); iii) except for compound 7, an alkaloid possessing a 16 -OMe (e.g. 4) is more active than the corresponding one without it (e.g. 26) and the one with a double bond between C-15 and C-16 (e.g. 24); iv) the alkaloids 7 and 8 that contain a 13-OH have significantly improved activity compared with their corresponding alkaloids 15 and 14 that lack the 13-OH, suggesting that this group is also a determining factor for the cardiac action. V) the effect of 6 -OMe on the cardiac activity depends on the substituent pattern on the nitrogen atom. Both NMe-containing compounds 7 and 22 did not show any cardiac activity, no matter with either the presence or absence of a 6 -OMe. However, introduction of 6 -OMe into the NHcontaining compound 21 led to compound 8 with enhanced cardiac effect.
In conclusion, the structure-cardiac activity relationships of diterpenoid alkaloids are summarized as below based on our previous and current studies: i)1 -OMe or 1 -OH, 8-OH, 14-OH, and NH (or NMe) are critical structural features necessary for the cardiac effect of the aconitine-type C 19 -diterpenoid alkaloids without any esters. C 18 -diterpenoid alkaloids, lycoctonine-type C 19diterpenoid alkaloids, and the veatchine-and denudatine-type C 20diterpenoid alkaloids did not possess any significant cardiac activity; ii) the existence of 3 -OH can significantly improve the cardiac activity; iii) the effects on the cardiac activity of 6 -OMe, 13-OH, 15 -OH, and 16-demethoxy or a double bond between C-15 and C-16 heavily depend upon the substituent pattern on the nitrogen atom; iv) interestingly, mesaconine hydrobromide (58) without showing any in vitro cardiac activity exhibited significant and quick in vivo efficacy that is comparable with the free base mesaconine (9) [8] . 
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Preparation of compound 4:
To a solution of compound 2 (150 mg, 0.26 mmol) in anhydrous THF (5 mL) was added sodium hydride (80%, 7 mg, 0.23 mmol), and the mixture was stirred at room temperature before the addition of methyl iodide (18 µL). The reaction was allowed to proceed with stirring for 2 h. Removal of the solvent afforded a residue, to which was added a solution of sodium hydroxide in methanol (5%, 6 mL). A general work-up afforded a crude product, which was purified by CC (silica gel, CHCl 3 -MeOH, 9:1) to give compound 4 (100 mg, 85%). 
Preparation of compound 6:
To a solution of chasmanine (5, 400 mg, 0.88 mmol) in acetic anhydride (6 mL) was added TsOH (400 mg), and the reaction was allowed to proceed with stirring at room temperature for 16 h. A general work-up provided a white solid, to which was added glacial acetic acid (20 mL) and NBS (710 mg). The subsequent reaction mixture was stirred at room temperature for 3 h before being concentrated. The white residue was subjected to CC on silica gel eluting with light petroleum: acetone:diethylamine (80:20:1) to furnish compound 6 (250 mg, 65%). 
Preparation of compound 7:
To a solution of compound 6 (114 mg, 0.26 mmol) in anhydrous THF (20 mL) was added sodium hydride (80%, 6 mg, 0.2 mmol), and the mixture was stirred at room temperature for 15 min before the addition of methyl iodide (14 µL). The reaction was allowed to proceed for 2 h at room temperature. A general work-up procedure gave a residue, to which was added a solution of sodium hydroxide in methanol (5%, 3 mL). The subsequent reaction mixture was stirred at 60 o C for 1 h and the solvent was removed in vacuo. The white foam was purified by CC eluting with CHCl 3 : MeOH: diethylamine (97:3:1) to yield compound 7 (83 mg, 74%). 
Preparation of compound 8:
To a solution of chasmanine (5, 600 mg, 1.32 mmol) in acetic anhydride (60 mL) was added TsOH (40 mg) and the reaction was allowed to proceed for 16 h. After a general work-up, the white residue was dissolved in glacial acetic acid (20 mL). To this solution was added NBS (713 mg, 4,00 mmol), and the subsequent reaction solution was stirred at room temperature for an additional 3 h. After the second standard workup, the crude product was purified by CC (silica gel, light petroleum: acetone, 4:1 with 1% diethylamine) to give compound 8 (440 mg, 65 %). 
Preparation of compound 13:
To a solution of indoconitine (12, 4 g, 6.4 mmol) in THF (12 mL) was added thionyl chloride (6 mL), and the reaction mixture was stirred at 40 o C for 2 h. Removal of volatile solvent gave a white solid, which was dissolved in ethanol (95%, 10 mL) and glacial acetic acid (2 mL). To the mixture was added 10% Pd-C and the reaction was allowed to proceed in the presence of hydrogen. A general work-up gave white foam, which was dissolved in glacial acetic acid (9 mL). To the subsequent mixture was added NBS (260 mg), and the reaction mixture was stirred at room temperature for 3 h. After a general work-up, the crude residue was purified by CC eluting with cyclohexane: acetone: diethylamine (75:25:1) to yield compound 13 ( 2.73 g, 71%).
Compound 13 
Preparation of compound 15:
To a solution of compound 13 (95 mg, 0.16 mmol) in anhydrous THF (5 mL) was added sodium hydride (80%, 5 mg), and the mixture was stirred for 15 min before the addition of methyl iodide (11 µL). The reaction was allowed to proceed for an additional 2 h. A standard work-up provided a white solid, to which was added a solution of sodium hydroxide in methanol (5%, 5 mL). The subsequent reaction mixture was stirred at 60 o C for 1 h prior to another standard work-up. The crude residue was purified by CC eluting with CHCl 3 : MeOH: diethylamine (97:3:1) to give compound 15 (24 mg, 71%). 
Preparation of compound 17:
To a solution of dexoyaconitine (17a, 315 mg, 0.50 mmol) in glacial acetic acid (10 mL) was added NBS (267 mg, 1.5 mmol), and the reaction mixture was kept stirred at room temperature for 3 h. A standard work-up procedure gave a crude residue, which was subjected to CC eluting with light petroleum: acetone: diethylamine (66:33:1) to furnish N-deethyldeoxyaconitine (24 mg, 80%). This compound was dissolved in a solution of sodium hydroxide in methanol (5%, 10 mL) and refluxed for 30 sec. After removing the solvent, the residue was dissolved in CHCl 3 : MeOH (9:3, 10 mL) and filtered. 
Preparation of compound 18:
To a solution of indaconitine (12, 440 mg, 0.7 mmol) in glacial acetic acid (12 mL) was added NBS (375 mg, 2.1 mmol), and the reaction was allowed to proceed at room temperature for 4 h prior to being basified with conc. ammonium hydroxide to pH 10. The subsequent mixture was extracted with CHCl 3 (20 mL × 3); the combined extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The crude residue was purified by CC eluting with light petroleum: acetone: diethylamine (75:25:1) to yield Ndeethylindeaconitine (329 mg, 78%). To the solution of this compound (300 mg, 0.5 mmol) in THF (10 mL) was added sodium hydride (80%, 15 mg, 0.5 mmol) followed by methyl iodide (35 l, 0.6 mmol) under argon. The subsequent reaction was allowed to proceed for 2 h before the solvent was removed. To the residue was added a solution of sodium hydroxide in methanol (15 mL), and the reaction was allowed to proceed with refluxing for an additional 1 h. The reaction mixture was first acidified with conc. HCl to pH 2 then basified with conc ammonium hydroxide to pH 10. The mixture was extracted with chloroform, and the combined extracts were dried over anhydrous sodium sulfate and concentrated. The crude residue was purified by CC eluting with CHCl 3 : MeOH (95:5, saturated with conc. ammonium hydroxide) to give compound 18 (185 mg, 78%). 
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Preparation of compound 21:
Compound 20 (100 mg, 0.20 mmol) was dissolved in a solution of sodium hydroxide in methanol (5%, 10 mL), and the reaction mixture was stirred at 60 o C for 1 h. After a general work-up procedure, the white residue was purified by CC eluting with CHCl 3 : MeOH: diethylamine (90:10:1) to generate compound 21 (24 mg, 30%). 
Preparation of compound 22:
To a solution of compound 20 (105 mg, 0.22 mmol) in THF (5 mL) was added sodium hydride (80%, 7 mg, 0.22 mmol), and the mixture was stirred for 15 min before the addition of methyl iodide (15 µL). The reaction was allowed to proceed with stirring at room temperature for 2 h. A general workup gave a white solid, to which was added a solution of sodium hydroxide in methanol (5%, 3 mL). The subsequent reaction mixture was stirred at 60 o C for an additional 1 h and then concentrated under reduced pressure. The crude residue was purified by CC on silica gel eluting with CHCl 3 : MeOH (97:3) to yield compound 22 (59 mg, 65%). 
Preparation of compounds 23, 24, 25 and 26:
Pyrolysis of 13deoxyindaconitine (1, 1.2 g, 1.95 mmol) at 180-190 o C under vacuum for 5 min followed by CC (light petroleum: acetone: diethylamine, 80:16:1) provided a white powder (650 mg, 62%). This was dissolved in acetic anhydride (25 mL), to which was added TsOH (200 mg). The subsequent solution was refluxed for 3 h prior to being cooled to 0 o C. The mixture was basified with conc. NH 4 OH to pH > 10, and extracted with chloroform 3 times. The combined extracts were dried over anhydrous sodium sulfate and concentrated in vacuo. The crude residue was subjected to CC eluting with light petroleum: acetone (5:1) to give a rearranged product (white amorphous powder, 590 mg, 80%). To a solution of this product in glacial acetic acid (10 mL) was added NBS (450 mg, 3 eq), and the reaction mixture was stirred at room temperature for 2 h. The mixture was cooled to 0 o C and basified with conc ammonium hydride to pH > 10, which was extracted with chloroform 3 times. The combined extracts were dried over anhydrous sodium sulfate and concentrated. The crude residue (520 mg) was dissolved in a solution of sodium hydroxide in methanol (5%) and stirred at 50 o C for 1 h. After removal of solvent, the residue was partitioned between water and ethyl acetate. The organic layers were dried over anhydrous sodium sulfate and concentrated in vacuo. The residue was purified by CC eluting with light petroleum: acetone: diethylamine (60:30:1) to yield compound 23 (white amorphous powder, 400 mg, 50%). To a solution of compound 23 (200 mg, 0.24 mmol) in THF was added sodium hydride (8.0 mg) and methyl iodide (20 µL), and the reaction was allowed to proceed at room temperature for 2 h. After removal of solvent, the residue was purified by CC eluting with chloroform: methanol (50:1) to give compound 24 (white amorphous powder,180 mg, 89%). To a solution of compound 23 (100 mg, 0.23 mmol) in 95% ethanol (3 mL) was added 2 drops of glacial acetic acid and Pt 2 O (10 mg). The reaction was allowed to proceed in the presence of hydrogen under 30 MPa for 20 h. The mixture was basified with conc. ammonium hydroxide to pH > 10. A standard work-up procedure followed by CC [chloroform: methanol (50:1)] yielded compound 25 (white amorphous powder, 90 mg, 89%). According to a similar procedure, hydrogenation of 24 (100 mg, 0.23 mmol), followed by CC (silica gel, CHCl 3 : MeOH = 100:1) gave compound 26 (87 mg, 87 %).
Compound 23 
Preparation of compound 35:
To a solution of compound 31a (110 mg, 0.17 mmol) in THF (5.5 mL) was added sodium hydride (4.1 mg, 0.17 mmol) and methyl iodide (10.7 uL, 0.17 mmol), and the reaction mixture was stirred at room temperature for 2 h. A general work-up gave a crude residue, to which was added a solution of sodium hydroxide in methanol (5%, 2 mL). The subsequent reaction mixture was stirred overnight and concentrated under reduced pressure. The crude residue was subjected to CC on silica gel eluting with CHCl 3 : MeOH (20:1) to yield compound 35 (34 mg, 84.1%).
Compound 35 
Preparation of compound 36:
To a solution of 13deoxyindaconitine (1, 200 mg, 0.28 mmol) in glacial acetic acid (10 mL) was added NBS (310 mg, 1.22 mmol), and the reaction was allowed to proceed at 130 o C for 10 h. A general work-up provided a residue, to which was added a solution of sodium hydroxide in methanol (5%, 10 mL). The subsequent reaction mixture was stirred at 50 o C for 1 h before removing the methanol. The crude residue was purified by CC eluting with CHCl 3 : MeOH (40:1) to give compound 36 (115 mg, 70%). 
Preparation of compound 38:
To a solution of lappaconitine (37, 2.336 g, 4 mmol) in glacial acetic acid (70 mL) was added NBS (2.136 g, 12 mmol), and the reaction was allowed to proceed at room temperature for 2 h. The reaction was quenched by pouring the reaction mixture into ice water, which was basified with conc ammonium hydroxide to pH 10 and extracted with chloroform (20 mL × 3). The combined extracts were dried over anhydrous sodium sulfate and concentrated. The residue (2.3 g) was purified by CC on silica gel eluting with light petroleum: acetone: diethylamine (75:25:1) to give N-deethyllappaconitine (38, 1.87 g, 84%). Preparation of compound 39: Compound 38 (300 mg, 0.54 mmol) was dissolved in a solution of sodium hydroxide in methanol (10%), and the mixture was stirred at 60 o C for 1 h and then basified with conc. NH 4 OH to pH 11. After removing the solvents, the residue was purified by CC eluting with CHCl 3 : MeOH (95:5 -9:1, saturated with conc. ammonium hydroxide) to furnish compound 39 (168 mg, 79%).
Compound 38

